Edition:
India

Bayer AG (BAYGn.DE)

BAYGn.DE on Xetra

59.30EUR
22 Mar 2019
Change (% chg)

€-1.98 (-3.23%)
Prev Close
€61.28
Open
€61.10
Day's High
€61.48
Day's Low
€59.20
Volume
5,107,733
Avg. Vol
3,484,492
52-wk High
€103.74
52-wk Low
€58.34

Chart for

About

Bayer AG is a life science company. The Company's segments are Pharmaceuticals, Consumer Health, Crop Science and Animal Health. The Pharmaceuticals segment focuses on researching, developing and marketing prescription products and specialty therapeutics especially in the areas of cardiology, oncology, gynecology, hematology and... (more)

Overall

Beta: 0.98
Market Cap(Mil.): €96,918.28
Shares Outstanding(Mil.): 826.95
Dividend: 2.70
Yield (%): 2.30

Financials

  BAYGn.DE Industry Sector
P/E (TTM): 22.18 29.30 32.54
EPS (TTM): 5.29 -- --
ROI: 8.69 14.23 13.82
ROE: 16.39 15.46 15.24

Bayer CEO says his team retains backing of supervisory board - report

FRANKFURT, March 24 Bayer's management retains the backing of its supervisory board, its chief executive said, after pressure on the company increased when a second jury in the United States ruled its glyphosate-based Roundup weed killer caused cancer.

24 Mar 2019

Jury finding upends Bayer's Roundup defense strategy: experts

NEW YORK Bayer AG had hoped a new trial strategy focusing jurors on scientific evidence could stem a burgeoning tide of U.S. lawsuits over its glyphosate-based weed killer Roundup, but a second jury finding on Tuesday that the product caused cancer has narrowed the company's options, some legal experts said.

21 Mar 2019

Jury finding upends Bayer's Roundup defence strategy: experts

NEW YORK Bayer AG had hoped a new trial strategy focusing jurors on scientific evidence could stem a burgeoning tide of U.S. lawsuits over its glyphosate-based weed killer Roundup, but a second jury finding on Tuesday that the product caused cancer has narrowed the company's options, some legal experts said.

21 Mar 2019

U.S. jury hears more evidence as second phase of Roundup cancer trial begins

SAN FRANCISCO A lawyer for a man who sued Bayer AG unit Monsanto after developing cancer on Wednesday told a jury about the company's alleged efforts to influence scientists and regulators, a day after the jury found Bayer's glyphosate-based weed killer Roundup to have caused the man's disease.

21 Mar 2019

U.S. jury hears more evidence as second phase of Roundup cancer trial begins

SAN FRANCISCO, March 20 A lawyer for a man who sued Bayer AG unit Monsanto after developing cancer on Wednesday told a jury about the company's alleged efforts to influence scientists and regulators, a day after the jury found Bayer's glyphosate-based weed killer Roundup to have caused the man's disease.

20 Mar 2019

European stocks break five-day rally; Bayer, BMW weigh on DAX

European shares retreated from near six-month highs on Wednesday, with German stocks leading losses as chemicals producer Bayer and carmaker BMW tumbled, and as the European Union resisted British Prime Minister Theresa May's plea to delay Brexit.

20 Mar 2019

UPDATE 1-European stocks break 5-day rally; Bayer, BMW weigh on DAX

* Bayer falls after second jury ruled against its weed killer

20 Mar 2019

GLOBAL MARKETS-Shares dip ahead of Fed decision; oil surges to 4-month peak

* Sterling falls as much as 0.9 pct to the dollar (Updates prices, comments, changes dateline from previous LONDON)

20 Mar 2019

Bayer shares slide after latest Roundup cancer ruling

FRANKFURT Shares in Germany's Bayer's fell more than 12 percent on Wednesday after a second U.S. jury ruled its Roundup weed killer caused cancer. | Video

20 Mar 2019

Bayer shares slide after latest Roundup cancer ruling

FRANKFURT Shares in Germany's Bayer's fell more than 12 percent on Wednesday after a second U.S. jury ruled its Roundup weed killer caused cancer. | Video

20 Mar 2019

Earnings vs. Estimates